(Correcting) misdiagnoses of asthma: A cost effectiveness analysis

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Pakhale, Smita ^a   Sumner, Amanda ^b   Coyle, Douglas ^c   Vandemheen, Katherine ^a   Aaron, Shawn ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Asthma costCanadian asthma costasthma cost savingsasthma secondary screeningeconomic analysis; epidemiology of asthma

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; MONTELUKAST; NEDOCROMIL SODIUM; PREDNISONE; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT;

ALGORITHM; ARTICLE; ASTHMA; CANADA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ERROR; DRUG COST; DRUG WITHDRAWAL; ECONOMIC ASPECT; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; LIFESPAN; PATIENT SELECTION; PHYSICIAN; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; MASS SCREENING; METHODOLOGY; MULTICENTER STUDY; PREVALENCE; RETROSPECTIVE STUDY;

ALGORITHMS; ANTI-ASTHMATIC AGENTS; ASTHMA; CANADA; COST-BENEFIT ANALYSIS; DIAGNOSTIC ERRORS; HEALTH CARE COSTS; HUMANS; MASS SCREENING; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 79956220928     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-27     Document Type: Article

References (22)

1. National Asthma Survey 2007, National Asthma Survey., http://www.cdc.gov/nchs/about/major/slaits/nas.htm
2. Statistics Canada Persons with asthma, by age and sex. 2009, Statistics Canada., http://www40.statcan.gc.ca/l01/cst01/health49a-eng.htm?sdi=asthma
3. Sharpe HM, Sin DD, Andrews EM, Cowie RL, Man P. Alberta Strategy to Help Manage Asthma (ASTHMA): a provincial initiative to improve outcomes for individuals with asthma. Healthc Q 2004, 7(3):55-60. 4.
4. Jin R, Choi BC, Chan BT, McRae L, Li F, Cicutto L, et al. Physician asthma management practices in Canada. Can Respir J 2000, 7(6):456-465.
5. O'Dowd LC, Fife D, Tenhave T, Panettieri RA. Attitudes of physicians toward objective measures of airway function in asthma. Am J Med 2003, 114(5):391-396. 10.1016/S0002-9343(03)00007-X, 12714129.
6. Diaz-Lobato S, Mayoralas S. Underuse of Spirometry in Primary Care. Chest 2004, 126(5):1712-1713. 10.1378/chest.126.5.1712, 15539755.
7. Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P, et al. Overdiagnosis of asthma in obese and nonobese adults. Can Med Assoc J 2008, 179(11):1121-1131.
8. McKnight-Eily L, Elam-Evans L, Strine T, Zack M, Perry G, Presley-Cantrell L, et al. Activity limitation, chronic disease, and comorbid serious psychological distress in U.S. adults ΓÇô BRFSS 2007. International Journal of Public Health 2009, 54(0):111-119.
9. Kamble S, Bharmal M. Incremental Direct Expenditure of Treating Asthma in the United States. Journal of Asthma 2009, 46(1):73-80. 10.1080/02770900802503107, 19191142.
10. Krahn MD, Berka C, Langlois P, Detsky AS. Direct and indirect costs of asthma in Canada, 1990. Can Med Assoc J 1996, 154(6):821-831.
11. Schedule of Benefits for Physician Services, edited on June 2008. , http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html
12. Ontario Drug Benefit Formulary/Comparative Drug Index Ministry of Health and Long-term Care of Ontario 2009. 2009, Ministry of Health and Long-term Care of Ontario, Ontario Drug Benefit Formulary/Comparative Drug Index.
13. Corrigan SP, Cecillon DL, Sin DD, Sharpe HM, Andrews EM, Cowie RL, et al. The costs of implementing the 1999 Canadian Asthma Consensus Guidelines recommendation of asthma education and spirometry for the family physician. Can Respir J 2004, 11(5):349-353.
14. Campbell MK, Togerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 1999, 92:177-182. 10.1093/qjmed/92.3.177, 10326078.
15. Luks VP, Vandemheen KL, Aaron SD. Confirmation of asthma in an Era of Overdiagnosis. Eur Respir J 2010, 09031936.
16. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003, 111(6):1212-1218. 10.1067/mai.2003.1449, 12789219.
17. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992, 326(13):862-866. 10.1056/NEJM199203263261304, 1542323.
18. Bahadori K, Doyle-Waters M, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulmonary Medicine 2009, 9(1):24. 10.1186/1471-2466-9-24, 2698859, 19454036.
19. Kenny P, Lancsar E, Hall J, King M, Chaplin M. The individual and health sector costs of asthma: the first year of a longitudinal study in New South Wales. Aust N Z J Public Health 2005, 29(5):429-435. 10.1111/j.1467-842X.2005.tb00222.x, 16255444.
20. Ungar WJ, Coyte PC, Chapman KR, MacKeigan L. The patient level cost of asthma in adults in south central Ontario. Pharmacy Medication Monitoring Program Advisory Board. Can Respir J 1998, 5(6):463-471.
21. Awadh BN, Grunfeld A, Fitzgerald JM. Health care costs associated with acute asthma: a prospective economic analysis. Can Respir J 1999, 6(6):521-525.
22. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978, 299(14):741-744. 10.1056/NEJM197810052991403, 692548.